[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19

Cancer Discov. 2020 Jun;10(6):775-778. doi: 10.1158/2159-8290.CD-20-0473. Epub 2020 Apr 17.

Abstract

Cytokine release and macrophage activation contribute to immunopathology after SARS-CoV-2 infection. We discuss approaches to decrease the morbidity and mortality in patients with COVID-19 by repurposing existing drugs previously developed for cancer therapy.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Betacoronavirus*
  • COVID-19
  • Calcineurin Inhibitors / therapeutic use
  • Cell- and Tissue-Based Therapy
  • Coronavirus Infections / complications*
  • Coronavirus Infections / epidemiology
  • Cytokines / metabolism
  • Drug Repositioning
  • Humans
  • Immunotherapy / methods*
  • Inflammation / epidemiology
  • Inflammation / etiology
  • Inflammation / therapy*
  • Lymphohistiocytosis, Hemophagocytic / etiology
  • Lymphohistiocytosis, Hemophagocytic / prevention & control
  • Lymphohistiocytosis, Hemophagocytic / therapy
  • Macrophage Activation
  • Morbidity
  • Neoplasms / therapy
  • Neoplasms / virology
  • Pandemics
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / epidemiology
  • Receptors, Antigen, T-Cell / immunology
  • SARS-CoV-2

Substances

  • Calcineurin Inhibitors
  • Cytokines
  • Receptors, Antigen, T-Cell